Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 2026-10-02			5-day change	1st Jan Change
922.63 ^PKR	-0.74%		-3.04%	-9.77%

Aug. 27	Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
May. 18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	48,884	-	-
Change	-	11.36%	-9.77%	-	-
Enterprise Value (EV)	48,650	54,175	48,884	48,884	48,884
Change	-	11.36%	-9.77%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.61x	1.43x	1.27x
EV / Revenue	-	0x	1.61x	1.43x	1.27x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.88%	5.64%	6.5%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	922.63	922.63	922.63
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	3/26/25	4/7/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.88%	177M
ELI LILLY AND COMPANY	32.45x	11.78x	23.93x	0.61%	1,019B
JOHNSON & JOHNSON	28.48x	6.32x	17.7x	2.09%	617B
ABBVIE INC.	33.26x	7.78x	16.08x	2.64%	464B
MERCK & CO., INC.	104.98x	5.87x	24.89x	2.36%	356B
ROCHE HOLDING AG	18.81x	4.58x	11.36x	2.9%	333B
NOVARTIS AG	19.83x	5.17x	12.78x	3.09%	267B
ASTRAZENECA PLC	20.02x	4.17x	11.86x	2.13%	244B
AMGEN INC.	25.46x	6.66x	11.86x	2.5%	218B
GILEAD SCIENCES, INC.	-43.78x	6.39x	24.97x	2.27%	179B
Average	26.61x	6.52x	17.27x	2.55%	369.74B
Weighted average by Cap.	31.80x	7.61x	18.61x	1.96%